Аннотация

Цель
To present data on the dynamics of selected clinical and epidemiological aspects of breast cancer (BC) in the Republic of Tajikistan over the period 2016 2023..
Материал и методы
The study analyzed data from the annual reporting Form No. 7 submitted to the Center for Medical Statistics and Information of the Ministry of Health and Social Protection of the Population of the Republic of Tajikistan (MoHSP RT) for the years 2016–2023. Additional data were obtained from the Departments of Mammology and Reconstructive Surgery and the Pathomorphology Laboratory of the Republican Scientific Oncological Center. The analysis included the number of newly diagnosed and deceased patients, age-specific incidence among women, results of immunohistochemical (IHC) testing of biopsy and surgical materials for oncologi-cal pathology, and data on the accessibility of cancer care services.
Результаты
According to official statistics, the number of newly diagnosed BC cases in the re-public increased by 1.5 to 1.7 times in 2022–2023 compared to 2016–2021. Meanwhile, BC death rate declined by 0.8 to 0.9 times. Stage I–II cancers accounted for 63–75% of cases, while stage III- IV comprised 10–21% and 10–17%, respectively. IHC analysis of tumors for estrogen and proges-terone receptors, Her-2neu, and Ki-67 revealed that the most common subtypes were luminal B Her-2neu-negative (43.5%) and triple-negative breast cancer (TNBC) (21.0%). Luminal A subtype ac-counted for 12.3%, luminal B Her-2neu-positive — 9.3%, and non-luminal Her-2neu positive — 13.9%.
Заключение
The observed increase in reported breast cancer cases in Tajikistan during 2022–2023 is associated with enhanced case detection efforts. IHC subtyping of tumors in 2023 revealed that the most prevalent biological subtypes were luminal B and triple negative breast cancers. Lim-ited access to targeted therapy among patients remains a pressing issue in the national oncology care system

Ключевые слова

Breast cancer morbidity and mortality IHC research surgical treatment

Полный текст

Скачать статью в PDF

Полная версия статьи в формате PDF

Список литературы

  1. Artamonova E.V. Kak dostich’ balansa mezhdu effektivnost’yu lecheniya i kachestvom zhizni pacienta s metastaticheskim rakom molochnoj zhelezy // Medicinskoe obozrenie. 2022. T. 6, № 6. S. 326–333.
  2. Kaprin A.D. Zlokachestvennye novoobrazovaniya v Rossii v 2019 godu (Zabolevaemost’ i smertnost’). Moskva: Medicina, 2020. 252 s.
  3. Rasulov S.R., Ganiev D.F. Dinamika zabolevaemosti i smertnosti ot raka molochnoj zhelezy v Respublike Tadzhikistan za 2016-2020 gg. // Vestnik poslediplomnogo obrazovaniya v sfere zdravoohraneniya. 2022. № 2. S. 52-56.
  4. Rahimova M.N. Epidemiologiya raka molochnoj zhelezy v stranah SNG i Respublike Kazahstan (literaturnyj obzor) // West Kazakhstan Medical journal. 2019. № 61(1). S. 46–55.
  5. Saribekyan E.K. Faktory prognoza lecheniya otechno-infil’trativnogo raka molochnoj zhelezy // Onkologiya. ZHurnal im. P.A. Gercena. 2014. T. 63, № 1. S. 10–13.
  6. Alejandro Martin Sanchez. New challenges in multimodal workout of locally advanced breast cancer // The surgeon, 2017, N 15(6), рр. 372-378.
  7. Kang S.Y. [et al.]. Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry // J Breast Cancer, 2020 Apr, Vol. 23, No. 2, рр. 115–28.
  8. Globocan 2022 (version 1.1) - 08.02.2024. International Agency for Research on Cancer. Cancer TODAY | IARC. [https://gco.iarc.who.int](https://gco.iarc.who.int)